IQVIA Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
IQVIA Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 13.8% bzw. 5.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 13.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 31.4% betragen.
Wichtige Informationen
13.8%
Wachstumsrate der Gewinne
13.5%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 18.5% |
| Wachstumsrate der Einnahmen | 5.3% |
| Zukünftige Eigenkapitalrendite | 31.4% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 15 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Nov 14
Is IQVIA Holdings (NYSE:IQV) A Risky Investment?
Oct 21IQVIA Holdings Inc.'s (NYSE:IQV) Business Is Trailing The Market But Its Shares Aren't
Sep 22IQVIA Holdings Inc. (NYSE:IQV) Shares Could Be 38% Below Their Intrinsic Value Estimate
Sep 08Reiterating Buy On IQVIA After Q2 Earnings
Aug 20With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Aug 11Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
Jul 30These 4 Measures Indicate That IQVIA Holdings (NYSE:IQV) Is Using Debt Reasonably Well
Jul 18An Intrinsic Calculation For IQVIA Holdings Inc. (NYSE:IQV) Suggests It's 33% Undervalued
Jun 04IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
May 27Is It Time To Consider Buying IQVIA Holdings Inc. (NYSE:IQV)?
Apr 24Is IQVIA Holdings (NYSE:IQV) Using Too Much Debt?
Apr 11IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Not Quite Adding Up
Mar 27Here's Why IQVIA Holdings (NYSE:IQV) Has Caught The Eye Of Investors
Mar 14IQVIA Holdings: Strong Q4 Results Suggest A Bullish 2024
Feb 22Is IQVIA Holdings Inc. (NYSE:IQV) Trading At A 29% Discount?
Jan 23Market Participants Recognise IQVIA Holdings Inc.'s (NYSE:IQV) Earnings
Dec 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Dec 08Should You Investigate IQVIA Holdings Inc. (NYSE:IQV) At US$205?
Nov 23IQVIA Q3: TAS Segment Remains The Problem Child
Nov 21IQVIA: I Would Stay Away Until Debt Issues Are Resolved
Nov 12Is There An Opportunity With IQVIA Holdings Inc.'s (NYSE:IQV) 32% Undervaluation?
Oct 08IQVIA: Stock To Remain Rangebound As I Expect Weak Numbers In The Near Term
Sep 07Is IQVIA Holdings (NYSE:IQV) A Risky Investment?
Sep 04Why IQVIA Holdings Inc. (NYSE:IQV) Could Be Worth Watching
Aug 11IQVIA Holdings Q2: Breaking Ground And Beating Expectations
Aug 03IQVIA Holdings Inc.'s (NYSE:IQV) Intrinsic Value Is Potentially 43% Above Its Share Price
Jun 27IQVIA Holdings (NYSE:IQV) Has A Pretty Healthy Balance Sheet
Jun 05IQVIA Holdings: A Possible Beat And Raise Scenario In The Works
May 23What Does IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Indicate?
May 04A Look At The Fair Value Of IQVIA Holdings Inc. (NYSE:IQV)
Mar 19Does IQVIA Holdings (NYSE:IQV) Have A Healthy Balance Sheet?
Mar 05Here's Why We Think IQVIA Holdings (NYSE:IQV) Might Deserve Your Attention Today
Feb 12IQVIA Q4 2022 Earnings Preview
Feb 09When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
Jan 29IQVIA Holdings: Premium Valuation Is Justified For An Industry Leader
Jan 24We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Nov 09IQVIA Holdings Sees Digital Opportunities, But Debt Drags Growth
Nov 02IQVIA Q3 2022 Earnings Preview
Oct 25Is Now The Time To Look At Buying IQVIA Holdings Inc. (NYSE:IQV)?
Oct 02IQVIA: Rebound Is Likely But Downtrend Is Still Intact (Technical Analysis)
Sep 19With EPS Growth And More, IQVIA Holdings (NYSE:IQV) Makes An Interesting Case
Aug 22GSK, Iqvia launch Vaccine Track platform to highlight vaccine trends publicly in US
Aug 11We Think IQVIA Holdings (NYSE:IQV) Can Stay On Top Of Its Debt
Aug 08IQVIA: Resiliency And Quality Never Left, Q2 Earnings Evidence The Same
Jul 28Are Investors Undervaluing IQVIA Holdings Inc. (NYSE:IQV) By 48%?
Jul 26IQVIA Non-GAAP EPS of $2.44 beats by $0.06, revenue of $3.54B beats by $50M, raises FY22 guidance
Jul 21Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 17,179 | 1,793 | 2,471 | 3,082 | 17 |
| 12/31/2025 | 16,243 | 1,536 | 2,148 | 2,735 | 22 |
| 12/31/2024 | 15,387 | 1,338 | 1,882 | 2,478 | 18 |
| 9/30/2024 | 15,315 | 1,405 | 1,961 | 2,578 | N/A |
| 6/30/2024 | 15,155 | 1,423 | 1,827 | 2,440 | N/A |
| 3/31/2024 | 15,069 | 1,357 | 1,624 | 2,254 | N/A |
| 12/31/2023 | 14,984 | 1,358 | 1,500 | 2,149 | N/A |
| 9/30/2023 | 14,855 | 1,116 | 1,321 | 1,962 | N/A |
| 6/30/2023 | 14,681 | 1,096 | 1,582 | 2,242 | N/A |
| 3/31/2023 | 14,494 | 1,055 | 1,508 | 2,169 | N/A |
| 12/31/2022 | 14,410 | 1,091 | 1,586 | 2,260 | N/A |
| 9/30/2022 | 14,307 | 1,182 | 1,705 | 2,392 | N/A |
| 6/30/2022 | 14,136 | 1,160 | 1,689 | 2,373 | N/A |
| 3/31/2022 | 14,033 | 1,079 | 1,915 | 2,583 | N/A |
| 12/31/2021 | 13,874 | 966 | 2,302 | 2,942 | N/A |
| 9/30/2021 | 13,536 | 767 | 2,368 | 3,000 | N/A |
| 6/30/2021 | 12,931 | 607 | 2,103 | 2,730 | N/A |
| 3/31/2021 | 12,014 | 409 | 2,039 | 2,663 | N/A |
| 12/31/2020 | 11,359 | 279 | 1,343 | 1,959 | N/A |
| 9/30/2020 | 10,956 | 176 | 1,215 | 1,792 | N/A |
| 6/30/2020 | 10,939 | 132 | 979 | 1,548 | N/A |
| 3/31/2020 | 11,158 | 215 | 885 | 1,467 | N/A |
| 12/31/2019 | 11,088 | 191 | 835 | 1,417 | N/A |
| 9/30/2019 | 10,881 | 244 | 668 | 1,251 | N/A |
| 6/30/2019 | 10,706 | 247 | 708 | 1,265 | N/A |
| 3/31/2019 | 10,533 | 248 | 673 | 1,185 | N/A |
| 12/31/2018 | 10,412 | 259 | 795 | 1,254 | N/A |
| 9/30/2018 | 10,245 | 1,217 | 647 | 1,070 | N/A |
| 6/30/2018 | 10,117 | 1,245 | N/A | 1,162 | N/A |
| 3/31/2018 | 9,905 | 1,246 | N/A | 1,096 | N/A |
| 12/31/2017 | 9,702 | 1,277 | N/A | 970 | N/A |
| 9/30/2017 | 9,133 | 72 | N/A | 1,184 | N/A |
| 6/30/2017 | 7,804 | 84 | N/A | 1,008 | N/A |
| 3/31/2017 | 6,616 | 108 | N/A | 804 | N/A |
| 12/31/2016 | 6,815 | 72 | N/A | 860 | N/A |
| 9/30/2016 | 4,540 | 397 | N/A | 620 | N/A |
| 6/30/2016 | 4,497 | 409 | N/A | 643 | N/A |
| 3/31/2016 | 4,404 | 408 | N/A | 652 | N/A |
| 12/31/2015 | 4,326 | 387 | N/A | 476 | N/A |
| 9/30/2015 | 4,262 | 371 | N/A | 525 | N/A |
| 6/30/2015 | 4,229 | 352 | N/A | 379 | N/A |
| 3/31/2015 | 4,191 | 353 | N/A | 396 | N/A |
| 12/31/2014 | 4,165 | 357 | N/A | 433 | N/A |
| 9/30/2014 | 4,106 | 341 | N/A | 391 | N/A |
| 6/30/2014 | 3,977 | 315 | N/A | 431 | N/A |
| 3/31/2014 | 3,886 | 268 | N/A | 386 | N/A |
| 12/31/2013 | 3,808 | 227 | N/A | 393 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IQVDas prognostizierte Gewinnwachstum (13.8% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: IQVDie Erträge des Unternehmens (13.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.3% pro Jahr).
Hohe Wachstumserträge: IQVDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: IQVDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: IQVDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: IQVDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (31.4%)